People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evecxia, Inc. | — | Biotechnology | Series A | $23.1M | $13.5M | 2025 |
| Nido Biosciences, Inc. | — | Biotech / Pharma | Series B | $22.4M | $636.4M | 2019 |
Elliot Ehrich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elliot Ehrich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Andrew Hedin | 1 | 5 |
| Roger Jeffs | 1 | 3 |
| Jacqueline Grant | 1 | 3 |
| David Zaccardelli | 1 | 2 |
| Jamil Beg | 1 | 2 |
| Thomas Aasen | 1 | 2 |
| John Kaiser | 1 | 2 |
| Allan Shaw | 1 | 2 |
| Marc Caron | 1 | 1 |
| Craig Robert Sincock | 1 | 1 |
| Jacob Jacobsen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.